Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.52 |
| ▸ | HPGD | P15428 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458676 | 0.92 | NAMPT (0.52) | NAMPTHPGDALDH1A1MAPT | |
| SCHEMBL10204342 | 0.85 | NAMPT (0.50) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1458052 | 0.81 | HPGD (0.60) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1458739 | 0.79 | EGLN1 (0.58) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1458599 | 0.79 | HRH4 (0.70) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL10204341 | 0.79 | CKS1B (0.57) | NAMPTHPGD | |
| SCHEMBL1458918 | 0.79 | HPGD (0.66) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1458615 | 0.79 | HPGD (0.66) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1457962 | 0.79 | HPGD (0.66) | NAMPTHPGDALDH1A1KDM4EGAA | |
| SCHEMBL1458839 | 0.79 | HPGD (0.66) | NAMPTHPGDALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-9868708-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-11 | — | — | US | disclosed |
| CN-102656163-B | Suppress the heterogeneous ring compound of PASK | BIOENERGENIX (US) | 2016-01-13 | — | — | CN | disclosed |
| US-9193693-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2473504-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20150031679-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8916560-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| CN-102656163-A | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX | 2012-09-05 | — | — | CN | disclosed |
| EP-2473504-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | Bioenergenix (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2011028947-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165318-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
| US-20160229815-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
| US-20150031679-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | NAMPT 544/4885HPGD 824/4885ALDH1A1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.